FDA clearance allows Prelude Therapeutics to advance PRT13722 into a Phase 1 study for HR+/HER2- breast cancer. The study is expected to begin enrolling patients in the fourth quarter of 2026 and will test the oral KAT6A degrader alone and with endocrine or targeted therapies, creating a defined clinical development milestone for investors.
Key Highlights
- Patient enrollment for the PRT13722 study is anticipated in the fourth quarter of 2026.
- The open-label, multicenter trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity.
- Investor materials identify early 2027 data for Prelude’s JAK2V617F mutant selective JH2 inhibitor program.
The first-in-human trial will evaluate the candidate in adults with locally advanced or metastatic disease.
PRT13722 Phase 1 Study Scope
The open-label, multicenter study will assess safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity. Prelude (NASDAQ: PRLD) describes the candidate as an oral, selective KAT6A degrader. The program is being developed for patients with HR-positive, HER2-negative breast cancer.
Fourth-Quarter 2026 Enrollment Plan
Those materials identify a Phase 1 start in the fourth quarter of 2026 for KAT6A selective degraders in HR+ breast cancer and other malignancies. The presentation identifies early data in 2027 for JAK2V617F mutant selective JH2 inhibitors in myeloproliferative neoplasms.
FAQs
Q: When will Prelude Therapeutics begin PRT13722 enrollment?
A: Prelude Therapeutics expects patient enrollment in the PRT13722 Phase 1 study to begin during the fourth quarter of 2026. The filing says the study follows FDA clearance under the company’s IND.
Q: Who will participate in the PRT13722 Phase 1 study?
A: The study is an open-label, multicenter Phase 1 trial in adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer. It will evaluate PRT13722 alone and with endocrine and targeted therapies.
Q: What will the PRT13722 study evaluate?
A: The study will assess safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of PRT13722. The filing describes it as an oral KAT6A selective degrader.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.